Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080301 · ClinicalTrials.gov registry record · Phase 3
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
A Phase 3 study, sponsored by R-Pharm.
- Completed
- Registry status
- Phase 3
- Development phase
- 752
- Enrollment target
NCT00080301 is a Phase 3 study that has completed, run by R-Pharm. The registered enrollment target is 752 participants.
The verdict
NCT00080301, a Phase 3 study, has completed, sponsored by R-Pharm.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 752 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine is better than capecitabine alone in shrinking or slowing the growth of the cancer in women with metastatic breast cancer who are resistant to taxane and received anthracycline chemotherapy. The safety of this treatment will also be studied.
Interventions
- DRUG Capecitabine
- DRUG Ixabepilone + Capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 752 participants |
| Start Date | 2003-09 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00080301
The ClinicalTrials.gov registry entry for NCT00080301 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 752 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is R-Pharm, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capecitabine is the first listed.
NCT00080301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00080301 about?
NCT00080301 is a clinical study titled "Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer". The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine is better than capecitabine alone in shrinking or slowing the growth of the cancer in women with metastatic breast cancer who are resistant to taxane and received anthracycline chemoth...
What is the current status of trial NCT00080301?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 752 participants. The study started on 2003-09. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00080301?
The interventions under investigation include: Capecitabine (DRUG), Ixabepilone + Capecitabine (DRUG).
Who is sponsoring clinical trial NCT00080301?
This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.